Nausea Clinical Trial
Official title:
Patient Recovery After Orthopedic Surgery Under Nerve Blocks With Sedation in Foot and Ankle Patients (FA) and Nerve Block With Either Sedation or General Anesthesia (GA) in Total Shoulder Arthroplasty (TSA) Patients. A Pilot Study
NCT number | NCT02602080 |
Other study ID # | 2015-397 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 2015 |
Est. completion date | April 2016 |
Verified date | September 2019 |
Source | Hospital for Special Surgery, New York |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Nausea after surgery may negatively influence patient satisfaction, may delay discharge, and cause unexpected hospital admissions. The trend toward ambulatory surgery has increased the focus on postoperative nausea, but published evidence is not based on standardized criteria for assessment. Therefore, the results for postoperative nausea are very diverse, especially reports on nausea incidence after regional anesthesia, i.e. spinal anesthesia. When peripheral nerve blocks have been applied for postoperative pain control, they significantly reduce postoperative pain, opioid consumption and side effects; patients receiving general anesthesia (GA) and nerve blocks are thought likely to have less nausea than patients receiving GA alone. This study is a pilot study looking at the incidence and intensity of nausea after orthopedic surgery under nerve blocks in foot and ankle (FA) patients and under nerve blocks with either sedation or GA in total shoulder arthroplasty (TSA) patients. The results of this study will help power a future randomized controlled trial, comparing the incidence and intensity of nausea in FA patients receiving GA through laryngeal mask airway (LMA) versus spinal anesthesia.
Status | Completed |
Enrollment | 55 |
Est. completion date | April 2016 |
Est. primary completion date | April 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Elective surgery - Age 18-99 - Patients who are capable to provide informed consent and answer questions in English, - For FA patients: Planned neuraxial anesthesia + nerve block for postsurgical analgesia, - For TSA patients: Planned brachial plexus nerve block + either general anesthesia or IV sedation. Exclusion Criteria: - Incapable to provide informed consent - Contraindications for regional or LMA anesthesia (anticoagulation, infection at injection site) - Anticipated difficult airway - Body mass index>35 - Anticipated surgical procedure time less than 1 hour or more than 4 hours, - History of severe postoperative nausea and/or vomiting - American Society of Anesthesiologists physical status classification >3 - Neuropathy - Pregnant or nursing women - Chronic opioid use (daily use of opioids one month prior to surgery/ patients requiring chronic pain interventions) - Prone position planned for surgery - Obstructive sleep apnea - Known allergy/sensitivity to any study medications |
Country | Name | City | State |
---|---|---|---|
United States | Hospital for Special Surgery, New York | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Hospital for Special Surgery, New York |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Nausea 1 Hour After Post-anesthesia Care Unit (PACU) Admission | Yes/no response to whether patient had nausea in the PACU 1 hour after admission. If yes, investigators will seek out intensity | 1 hour after surgery | |
Primary | Number of Participants With Nausea | Yes/no question. If yes, the investigators will then seek intensity of nausea. | Average 2 hours after surgery (at discharge from the recovery room after surgery) | |
Primary | Intensity of Nausea | On an 11 grade Likert scale (0=no nausea, 10=worst possible nausea) | 1 hour after surgery | |
Primary | Intensity of Nausea | On a 11 grade Likert scale (0=no nausea, 10=worst possible nausea) | 2 hours after surgery | |
Secondary | Antiemetic Consumption | Yes/no question if antiemetic consumption occured. | Duration of stay in recovery room after surgery (average 2 hours) | |
Secondary | Number of Participants With Emesis | Yes/no question. If yes, the investigators will then seek intensity of emesis | 1 hour after surgery | |
Secondary | Number of Participants With Emesis | Yes/no question. If yes, the investigators will then seek intensity of emesis | Average 2 hours after surgery (at discharge from the recovery room after surgery) | |
Secondary | Number of Participants Satisfied With Anesthesia | Lowest satisfaction score on a 11 grade Likert scale (0=no satisfaction, 10=maximal satisfaction). | PACU before discharge, an average of 2 hours | |
Secondary | Patients Receiving Opioids in the PACU | Yes/no for patients that were given opioids for pain management in the PACU. If opioids were consumed, the oral morphine equivalents for the patients taking opioids was totaled. | PACU stay before discharge (average 2 hours) | |
Secondary | Opioid Dose Among Patients Receiving Opioids in the PACU | Total opioid dose taken by patients who took any opioids in the PACU, measured in oral morphine equivalents (mg OME) | Duration of PACU stay (Average 2 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
Completed |
NCT02939287 -
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
|
Phase 3 | |
Not yet recruiting |
NCT06464926 -
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
|
N/A | |
Not yet recruiting |
NCT06055192 -
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
|
||
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT02462811 -
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
|
Phase 3 | |
Completed |
NCT01007500 -
Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery
|
Phase 4 | |
Recruiting |
NCT00528554 -
Laser Acupuncture Against Nausea in Children
|
N/A | |
Completed |
NCT00537875 -
Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens
|
N/A | |
Completed |
NCT00394966 -
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00947128 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
|
Phase 1 | |
Completed |
NCT00946387 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT05433636 -
Mindful Waiting Room
|
N/A | |
Not yet recruiting |
NCT04827108 -
Psychometric Properties of the Chinese Version of PeNAT
|
||
Not yet recruiting |
NCT04853303 -
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Recruiting |
NCT04181346 -
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
Recruiting |
NCT03679182 -
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
|
Phase 2 | |
Completed |
NCT02618343 -
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
|
N/A | |
Terminated |
NCT01405924 -
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
|
Phase 2 |